Protembis Receives Funding to Advance its Brain Protection Tech

German meditech firm Protembis has gained €20 million in venture-debt financing from the European Investment Bank (EIB) to develop a next-generation brain protection device.
 
The funding will support clinical trials, research, development and market access for the ProtEmbo cerebral embolic protection system, a filter device that deflects embolic material away from cerebral arteries during left-sided heart procedures including transcatheter aortic valve replacement (TAVR), thereby countering risks including stroke and cognitive decline.
 
“This agreement demonstrates our commitment to supporting companies such as Protembis that aim to improve the health and well-being of European citizens. Their innovative technology, developed in Europe, will save patients who have to undergo heart surgery, from suffering grave side effects like cerebral embolic events,” EIB Vice President Nicola Beer said.
 
The EIB accord with Protembis is supported by the InvestEU programme to trigger more than €372 billion in additional investment in new technologies until 2027. The deal is aligned with the InvestEU objective of promoting R&D and innovation.
 
“We are pleased to announce the signature of this agreement with the EIB,” Protembis Co-CEOs Karl von Mangoldt and Conrad Rasmus stated. “We would like to recognize the hard work, skill, and professionalism of the EIB team while thanking our existing investors and our board for their unwavering belief in the benefits of this additional financing facility.”
 
TAVR is a minimally invasive X-ray guided procedure to replace an aortic valve that has narrowed and doesn’t open fully. Globally, aboutd 430,000 patients with severe aortic stenosis are expected to be treated with TAVR by 2025.
 
A significant complication of TAVR is the risk of dislodging debris that lines the aortic arch and the old aortic valve. This debris can travel to the brain through three major arteries that originate in the roof of the aortic arch and can block smaller vessels in the brain and create lesions, which may cause stroke or contribute to acceleration of cognitive decline. ProtEmbo is inserted during TAVR via the artery in the left wrist, and lines the roof of the aortic arch, shielding the brain from the dislodged debris.
 
In March 2024, Protembis completed a €30 million Series B financing round to advance a pivotal U.S. Food and Drug Administration-approved Investigational Device Exemption study called the ProtEmbo trial. Enrolling between 250 and 500 patients undergoing TAVR in Europe and the United States, the study aims to show the superiority of ProtEmbo by randomizing against a hybrid control group: half of the group receiving no protection and half receiving the current predicate system, Boston Scientific Corp.’s “Sentinel.”

 
The European Investment Bank (EIB) is a long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy goals. It works closely with other EU institutions to foster European integration, promote the development of the European Union and support EU policies in more than 140 countries worldwide.
 
The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps mobilize private investments for the European Union’s policy priorities, such as the European Green Deal and the digital transition. The InvestEU programme brings together under one roof the multitude of EU financial instruments currently available to support investment in the European Union, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub and the InvestEU Portal. The InvestEU Fund is implemented through financial partners that will invest in projects using the EU budget guarantee of €26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment.
 
Protembis is a privately held emerging medical device company that has developed the ProtEmbo Cerebral Protection System. The company strives to provide a simple and reliable solution to protect patients from brain injury during left-sided heart procedures, improving patient quality of life and reducing overall healthcare costs associated with brain injury during such procedures. The ProtEmbo System is currently undergoing clinical investigations.